HUP0100670A2 - Vírusokat tartalmazó készítmények és eljárások víruspreparátumok töményítésére - Google Patents

Vírusokat tartalmazó készítmények és eljárások víruspreparátumok töményítésére

Info

Publication number
HUP0100670A2
HUP0100670A2 HU0100670A HUP0100670A HUP0100670A2 HU P0100670 A2 HUP0100670 A2 HU P0100670A2 HU 0100670 A HU0100670 A HU 0100670A HU P0100670 A HUP0100670 A HU P0100670A HU P0100670 A2 HUP0100670 A2 HU P0100670A2
Authority
HU
Hungary
Prior art keywords
virus
preparations
concentration
compositions
viruses
Prior art date
Application number
HU0100670A
Other languages
English (en)
Inventor
Laureano L. Bondoc
Andreas Frei
Peter Ihnat
Henry K. H. Kwan
Frederick William Porter Iv
Varda E. Sandweiss
John Chu-Tay Tang
Gary J. Vellekamp
Pui-Ho Yuen
Original Assignee
Schering Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp. filed Critical Schering Corp.
Publication of HUP0100670A2 publication Critical patent/HUP0100670A2/hu
Publication of HUP0100670A3 publication Critical patent/HUP0100670A3/hu
Publication of HU226015B1 publication Critical patent/HU226015B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material

Abstract

A találmány tárgyát új, vírustartalmú készítmények képezik, valamintúj eljárások vírustartalmú, különösen vírusvektorokat tartalmazókészítmények töményítésére és tisztítására. A készítményekpolihidroxi-szénhidrogén-puffert tartalmaznak a pH körülbelül 7 éskörülbelül 8,5 közötti tartományban tartása céljából, körülbelül 2 °Cés 27 °C közötti hőmérséklet-tartományban. A találmány szerintikészítmények szignifikánsan javított stabilitással rendelkeznek éskülönösen hasznosak terápiás alkalmazásokban, például génterápiában.Meglévő víruspreparátumok töményítésére szolgáló eljárásban avíruspreparátum anioncserélő kromatográfiára kerül, majd avíruspreparátum-termékhez hozzáadnak polihidroxi-szénhidrogént, éstangenciális áramlással való szűréssel növelik a víruspreparátum-termékben lévő vírus koncentrációját, és egy további feldolgozásilépésben méretkizáráson alapuló kromatográfiát végeznek. Ó
HU0100670A 1998-02-17 1999-02-12 Compositions and preparations comprising viruses HU226015B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2446298A 1998-02-17 1998-02-17
US7964398A 1998-05-15 1998-05-15
PCT/US1999/001873 WO1999041416A2 (en) 1998-02-17 1999-02-12 Compositions comprising viruses and methods for concentrating virus preparations

Publications (3)

Publication Number Publication Date
HUP0100670A2 true HUP0100670A2 (hu) 2001-06-28
HUP0100670A3 HUP0100670A3 (en) 2003-10-28
HU226015B1 HU226015B1 (en) 2008-02-28

Family

ID=26698472

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0100670A HU226015B1 (en) 1998-02-17 1999-02-12 Compositions and preparations comprising viruses

Country Status (25)

Country Link
EP (4) EP1526173B1 (hu)
JP (3) JP4358434B2 (hu)
KR (5) KR100918187B1 (hu)
CN (2) CN101164623B (hu)
AR (3) AR020054A1 (hu)
AT (3) ATE341614T1 (hu)
AU (1) AU757976B2 (hu)
BR (1) BR9908015A (hu)
CA (2) CA2320419C (hu)
CO (1) CO4820440A1 (hu)
DE (3) DE69933433T2 (hu)
DK (1) DK1054955T3 (hu)
ES (2) ES2290613T3 (hu)
HK (3) HK1073481A1 (hu)
HU (1) HU226015B1 (hu)
ID (1) ID28298A (hu)
IL (2) IL137510A0 (hu)
MY (1) MY141641A (hu)
NO (1) NO20004104L (hu)
PE (1) PE20000265A1 (hu)
PL (1) PL197747B1 (hu)
PT (1) PT1054955E (hu)
SK (1) SK11842000A3 (hu)
TW (1) TWI232107B (hu)
WO (1) WO1999041416A2 (hu)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
JP4492826B2 (ja) 1996-11-20 2010-06-30 イントロジェン セラピューティクス，インコーポレイテッド アデノウイルスベクターの産生および精製のための改良された方法
EP1133316B1 (en) * 1998-11-16 2009-01-21 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
EP1263461A4 (en) * 2000-03-07 2009-08-12 Merck & Co Inc ADENOVIRUS FORMULATIONS
US7456009B2 (en) 2000-03-07 2008-11-25 Merck & Co., Inc. Adenovirus formulations
US20020064860A1 (en) 2000-11-29 2002-05-30 Schering Corporation Method for purifying adenoviruses
AU2002218535A1 (en) * 2000-12-12 2002-06-24 Japan Tobacco Inc. Pharmaceutical composition containing an active with a hemolytic action and a surfactant
CA2469491A1 (en) 2001-12-12 2003-06-19 Kerrie Setiawan Composition for viral preservation
US20030153065A1 (en) * 2002-01-14 2003-08-14 Genvec, Inc. Composition and method for maintaining non-enveloped viral vectors
MXPA04006995A (es) * 2002-01-18 2005-07-13 Schering Ag Formulaciones estabilizadas de adenovirus.
ATE435906T1 (de) 2004-02-23 2009-07-15 Crucell Holland Bv Verfahren zur reinigung von viren
CA2586107A1 (en) 2004-11-03 2006-05-18 Introgen Therapeutics Inc. A novel method for the production and purification of adenoviral vectors
EP1831352B1 (en) 2004-12-13 2011-07-13 CANJI, Inc. Cell lines for production of replication-defective adenovirus
DK1869171T4 (en) 2005-04-11 2016-01-18 Crucell Holland Bv Virus cleaning using ultrafiltration
CN1961961B (zh) * 2005-11-11 2010-05-26 深圳市源兴生物医药科技有限公司 一种药物制剂及其制备方法
WO2007070392A2 (en) 2005-12-12 2007-06-21 Canji, Inc. Adenoviral expression vectors having an expression cassette in the e1 region and an inactivated e2b polymerase
WO2007123961A2 (en) * 2006-04-20 2007-11-01 Wyeth Purification processes for isolating purified vesicular stomatitis virus from cell culture
US10041049B2 (en) 2008-11-03 2018-08-07 Janssen Vaccines & Prevention B.V. Method for the production of adenoviral vectors
MX356669B (es) 2009-05-02 2018-06-08 Genzyme Corp Terapia genica para trastornos neurodegenerativos.
CA2786835C (en) 2010-02-15 2021-08-31 Crucell Holland B.V. Method for the production of ad26 adenoviral vectors
WO2012038367A1 (en) 2010-09-20 2012-03-29 Crucell Holland B.V. Therapeutic vaccination against active tuberculosis
WO2012041669A1 (en) 2010-09-27 2012-04-05 Crucell Holland B.V. Heterologous prime boost vaccination regimen against malaria
US9045728B2 (en) * 2010-12-02 2015-06-02 Oncolytics Biotech Inc. Liquid viral formulations
TW201233803A (en) 2010-12-02 2012-08-16 Oncolytics Biotech Inc Lyophilized viral formulations
SG194449A1 (en) * 2011-04-29 2013-12-30 Oncolytics Biotech Inc Methods of purifying viruses using gel permeation chromatography
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
KR102044051B1 (ko) 2012-03-12 2019-11-12 얀센 백신스 앤드 프리벤션 비.브이. 터미널 말단이 변경된 재조합 아데노바이러스의 배치
US9125870B2 (en) 2012-03-22 2015-09-08 Crucell Holland B.V. Vaccine against RSV
WO2013139916A1 (en) 2012-03-22 2013-09-26 Crucell Holland B.V. Vaccine against rsv
DK2988780T3 (en) 2013-04-25 2019-04-08 Janssen Vaccines & Prevention Bv STABILIZED SOLVEN RSV-F PREFUSION POLYPTIDES
US10294279B2 (en) 2013-06-17 2019-05-21 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F polypeptides
KR20170004966A (ko) * 2014-05-28 2017-01-11 에이전시 포 사이언스, 테크놀로지 앤드 리서치 바이러스 감소 방법
PL3283634T3 (pl) 2015-04-14 2019-10-31 Janssen Vaccines & Prevention Bv Rekombinowany adenowirus eksprymujący dwa transgeny z dwukierunkowym promotorem
BR112017027448A2 (pt) 2015-07-07 2018-09-04 Janssen Vaccines & Prevention Bv vacina contra rsv
BR112017028449A2 (pt) 2015-07-07 2018-09-04 Janssen Vaccines & Prevention Bv polipeptídeos rsv f pré-fusão solúveis estabilizados
CA3018139A1 (en) 2016-04-05 2017-10-12 Janssen Vaccines & Prevention B.V. Vaccine against rsv
SG11201807913XA (en) 2016-04-05 2018-10-30 Janssen Vaccines & Prevention Bv Stabilized soluble pre-fusion rsv f proteins
SG11201810078PA (en) 2016-05-30 2018-12-28 Janssen Vaccines & Prevention Bv Stabilized pre-fusion rsv f proteins
EP3472327B1 (en) 2016-06-20 2020-08-19 Janssen Vaccines & Prevention B.V. Potent and balanced bidirectional promoter
US10744196B2 (en) 2016-07-14 2020-08-18 Janssen Vaccines & Prevention B.V. HPV vaccines
WO2018210871A1 (en) 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
US11229692B2 (en) 2017-05-17 2022-01-25 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against RSV infection
WO2019021305A1 (en) * 2017-07-24 2019-01-31 Ella Foundation VACCINE AGAINST FOOT AND MOUTH DISEASE
EP3681533A1 (en) 2017-09-15 2020-07-22 Janssen Vaccines & Prevention B.V. Method for the safe induction of immunity against rsv
EP3990031A4 (en) * 2019-06-28 2023-08-09 Takeda Pharmaceutical Company Limited METHODS FOR PURIFYING ADENO-ASSOCIATED VIRUS
JP2023512519A (ja) 2020-01-31 2023-03-27 ベス イスラエル ディーコネス メディカル センター インコーポレイテッド コロナウイルス感染症を予防および処置するための組成物および方法－ｓａｒｓ－ｃｏｖ－２ワクチン
JP2024509756A (ja) 2021-02-19 2024-03-05 ヤンセン ファッシンズ アンド プリベンション ベーフェー 安定化された融合前ｒｓｖ ｆｂ抗原
WO2023020939A1 (en) 2021-08-17 2023-02-23 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
CN115989321A (zh) * 2021-08-17 2023-04-18 上海行深生物科技有限公司 病毒制剂、用于配制病毒制剂的溶液及其用途
WO2023111725A1 (en) 2021-12-14 2023-06-22 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE299213C (hu) *
US4147772A (en) * 1976-02-03 1979-04-03 Merck & Co., Inc. Vaccine stabilizer
GB1575155A (en) * 1978-04-11 1980-09-17 Merck & Co Inc Vaccine stabilizer
BE866330A (fr) * 1978-04-25 1978-10-25 Merck & Co Inc Procede de fabrication d'un agent de stabilisation de vaccin
US5532220A (en) 1987-08-31 1996-07-02 The Regents Of The University Of California Genetic mechanisms of tumor suppression
DD299213A7 (de) * 1988-05-04 1992-04-09 Saechsische Landesgewerbefoerderungsgesellschaft M.B.H.,De Verfahren zur stabilisierung eines lebendvirusimpfstoffes gegen temperatureinwirkung
DD295927A5 (de) * 1988-05-06 1991-11-14 Saechsisches Serumwerk Gmbh Dresden, Immobilisiertes immunologisch aktives reagens
EP2113569A1 (en) 1993-10-25 2009-11-04 CANJI, Inc. Recombinant adenoviral vector and methods of use
KR100368686B1 (ko) * 1994-12-29 2003-12-01 주식회사 엘지생명과학 수크로즈를이용한세포와바이러스의분리방법
FR2742756B1 (fr) * 1995-12-22 1998-04-03 Pasteur Merieux Serums Vacc Stabilisants pour vaccins vivants, vaccins les contenant et procedes pour leur preparation
US5789244A (en) * 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems

Also Published As

Publication number Publication date
AR063314A2 (es) 2009-01-21
ES2272053T3 (es) 2007-04-16
EP1526173A2 (en) 2005-04-27
WO1999041416A2 (en) 1999-08-19
KR20090127947A (ko) 2009-12-14
PL342847A1 (en) 2001-07-16
AR020054A1 (es) 2002-04-10
SK11842000A3 (sk) 2001-05-10
HK1073481A1 (en) 2005-10-07
AU2653899A (en) 1999-08-30
CA2320419C (en) 2011-02-08
PE20000265A1 (es) 2000-04-25
DE69933433D1 (de) 2006-11-16
KR100862169B1 (ko) 2008-10-09
DE69936948D1 (de) 2007-10-04
JP2010213727A (ja) 2010-09-30
HK1028416A1 (en) 2001-02-16
JP2006166925A (ja) 2006-06-29
AU757976B2 (en) 2003-03-13
EP1054955B1 (en) 2006-10-04
CO4820440A1 (es) 1999-07-28
EP1054955A2 (en) 2000-11-29
EP1741777A1 (en) 2007-01-10
KR20090038927A (ko) 2009-04-21
KR20080065615A (ko) 2008-07-14
KR100912362B1 (ko) 2009-08-19
EP1526173A3 (en) 2005-08-10
CA2723040A1 (en) 1999-08-19
DE69942708D1 (de) 2010-10-07
IL137510A (en) 2012-10-31
ATE371020T1 (de) 2007-09-15
EP1526174A3 (en) 2005-08-31
CN100374551C (zh) 2008-03-12
HK1097413A1 (en) 2007-06-22
CN101164623A (zh) 2008-04-23
IL137510A0 (en) 2001-07-24
WO1999041416A3 (en) 1999-11-18
NO20004104L (no) 2000-10-17
DE69936948T2 (de) 2008-05-15
KR20080065614A (ko) 2008-07-14
TWI232107B (en) 2005-05-11
DE69933433T2 (de) 2007-08-23
CA2320419A1 (en) 1999-08-19
KR100918187B1 (ko) 2009-09-22
HUP0100670A3 (en) 2003-10-28
CN1297478A (zh) 2001-05-30
ES2290613T3 (es) 2008-02-16
EP1526174B1 (en) 2007-08-22
ID28298A (id) 2001-05-10
KR100991683B1 (ko) 2010-11-04
PT1054955E (pt) 2007-01-31
ATE478945T1 (de) 2010-09-15
KR101018992B1 (ko) 2011-03-07
JP2002503484A (ja) 2002-02-05
HU226015B1 (en) 2008-02-28
MY141641A (en) 2010-05-31
ATE341614T1 (de) 2006-10-15
EP1741777B1 (en) 2010-08-25
KR20010072547A (ko) 2001-07-31
CN101164623B (zh) 2012-11-14
EP1526173B1 (en) 2012-11-21
NO20004104D0 (no) 2000-08-16
DK1054955T3 (da) 2007-01-15
JP4358434B2 (ja) 2009-11-04
PL197747B1 (pl) 2008-04-30
EP1526174A2 (en) 2005-04-27
BR9908015A (pt) 2001-04-24
AR063315A2 (es) 2009-01-21

Similar Documents

Publication Publication Date Title
HUP0100670A2 (hu) Vírusokat tartalmazó készítmények és eljárások víruspreparátumok töményítésére
Carroll et al. Monomer molecular weight of T antigen from simian virus 40-infected and transformed cells.
ES2349046T3 (es) Métodos para purificar virus.
Seidel et al. The conformation of myosin during the steady state of ATP hydrolysis: studies with myosin spin labeled at the S1 thiol groups
Duesberg et al. Structural relationships between the RNA of mammary tumor virus and those of other RNA tumor viruses
BR0013277A (pt) Derivados de 3(5) ureido-pirazol, processo para sua preparação e uso dos mesmos como agentes antitumorais
DK0743949T3 (da) Fremgangsmåde til fremstilling af endotoksinfrie eller endotoksinfattige nukleinsyrer og/eller oligonukleotider til gentera
FR2716682B1 (fr) Procédé de préparation de virus adéno-associés (AAV) recombinants et utilisations.
DE69532369D1 (de) Rekombinantes infektiöses nicht-in-Segmente-geteiltes, negativ-Strange-RNS-Virus
HUP0102478A2 (hu) A HCV-burokfehérjék által alkotott részecskék alkalmazása vakcinázásban
Levinson et al. Presence of DNA in Rous sarcoma virus
JPH0112760B2 (hu)
HUP0303431A2 (hu) PRRS vírus élő legyengített törzsei
Dietzschold et al. Serological characterization of the three major proteins of vesicular stomatitis virus
EP0192988A3 (en) Process for solubilization, purification and characterization of protein from insoluble protein aggregates or complexes and compositions of matter therefrom
CA2069460A1 (en) Methods and compositions for preparation and use of a herpes protease
Durban et al. Purification and characterization of a nuclear DNA-binding phosphoprotein in fetal and tumor tissues
Patton et al. Cell-free synthesis and assembly of vesicular stomatitis virus nucleocapsids
NO20051561L (no) Nukleinsyremolekyler som koder for humant papillomavirus og anvendelse av disse i vaksine.
Litman et al. Evidence for a conformational change in the 30 S E. coli ribosomal subunit upon formation of 70 S particles
Borecký et al. Electrophoretic profiles and activities of human interferon in heterologous cells
Yuen et al. Improved infectivity of reassembled polyoma virus
Graziadei III et al. Translation of reovirus messenger ribonucleic acids synthesized in vitro into reovirus proteins in a mouse L cell extract
Ohashi et al. I-Protein, a New Regulatory Protein from Vertebrate Skeletal Muscle I. Purification and Characterization
Simizu et al. A variant of western equine encephalitis virus with nonglycosylated E3 protein

Legal Events

Date Code Title Description
MM4A Lapse of definitive patent protection due to non-payment of fees